Tag archive for ‘Royalty deal with Royalty Partners on Omecamtiv’
Cytokinetics: Discussion of Financing Deal with Royalty Partners (CYTK, Buy, $11)
Terms and Implications of This Deal Cytokinetics announced that it had concluded a deal to sell a portion of the future royalty stream on omecamtiv to Royalty Partners, perhaps the leading purveyor of this type of financial instrument. Omecamtiv is partnered with Amgen and recently entered the phase 3 GALACTIC HF trial which will enroll […]